Edgar Filing: Revance Therapeutics, Inc. - Form 4

Revance Therapeu Form 4	utics, Inc.								
March 06, 2014									
FORM 4	UNITED	STATES	SECU	RITIES A	AND EX	CHANG	E COMMISSIO		APPROVAL
Charle this have				ashington				Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Estimated burden ho response	urs per
may continue. <i>See</i> Instruction 1(b).	Section 17(nvestmen	-			on	
(Print or Type Respon	ises)								
1. Name and Address of Reporting Person <u>*</u> Russell Angus C.		2. Issuer France and Frener of Frauing			Issuer	elationship of Reporting Person(s) to r			
		Middle)	3. Date of Earliest Transaction				(Ch	le)	
C/O REVANCE INC., 7555 GATI BOULEVARD	THERAPE			Day/Year)	Tunsuetron		X Director Officer (giv below)		% Owner her (specify
(S NEWARK, CA 9	Street) 94560			endment, D onth/Day/Yea	-	al	6. Individual or Applicable Line) _X_ Form filed by Form filed by Person		Person
(City) (S	State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities	Acquired, Disposed	of, or Beneficia	ally Owned
	nsaction Date h/Day/Year)		Date, if		4. Securit mAcquired Disposed (Instr. 3, Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report on	a separate line	e for each cl	ass of sec	urities bene	-	-	-		
					inforr requi	nation cor red to resp ays a curre	espond to the colle ntained in this form bond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)
	Tab						r Beneficially Owner e securities)	d	
1. Title of 2.	3. Trans	action Date	3A. Dec	emed	4.	5. Numbe	er of 6. Date Exerc	isable and	7. Title and Amo

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	J

E

Edgar Filing: Revance Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	` ·	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (E) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 28.71	03/04/2014		A	18,000	<u>(1)</u>	03/03/2024	Common Stock	18,000	

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Russell Angus C. C/O REVANCE THERAPEUTICS, IN 7555 GATEWAY BOULEVARD NEWARK, CA 94560	C. X						
Signatures							
/s/ Gordon Ho, Attorney-in-fact	8/06/2014						

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Option shares shall vest as follows: The shares subject to the Option Grant will vest on the one year anniversary of March 4, 2014, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C